TWM568137U - Encapsulated particle coated with lion's mane mushroom powder - Google Patents

Abstract

An embedded granule coated with a powder of Hericium erinaceus, comprising a plurality of Hericium erinaceus powder, a gelatinous substance layer and an edible shell layer. The Hericium erinaceus powder has a diameter ranging from 10 microns to 12 microns. The gelatinous substance layer coats the Hericium erinaceus powder. The edible shell layer coats the layer of the gelatinous substance.

Description

Encapsulated particles coated with Hericium erinaceus powder

This creation relates to the field of health foods, and more particularly to an embedded particle coated with a powder of Hericium erinaceus.

The global population is aging, and neurodegenerative diseases are receiving increasing attention. Among them, the prevalence of Parkinson's disease is rising steadily in Taiwan at an annual rate of 7.9% per year. Clinical treatment is to supplement patients with dopamine. Lord (levodopa / Levodopa). The current treatment is not a cure, although effective, but after 2-5 years of long-term medication, the efficacy will gradually weaken (Wearing-off) and eventually lose efficacy. From the perspective of preventive medicine, it is different from the efficacy of drug treatment for diseases, focusing on the concept of neuroprotection, and developing healthy foods that are strictly controlled by the process, effective in the analysis of functional components, scientifically validated and safely certified, except feasible. Prevention is better than cure, promoting health and delaying aging. It can also alleviate the burden of national medical expenditure and social welfare caused by the aging population and the increase of chronic diseases.

Hericium erinaceus belongs to the family Herricaceae, a genus of the genus Hericium, which has been used in China for the treatment of gastritis for thousands of years. According to the "Chinese Medicinal Fungi", it is sweet, flat, can benefit the five internal organs, help digestion, nourish, and has good effects on indigestion, neurodegenerative, duodenal ulcer and gastric ulcer. The modern scientific literature should also prove its efficacy. The polysaccharide extract of Hericium erinaceus can regulate the immune activity of ICRs mice and has a significant anticancer effect on metastatic lung cancer. In terms of immunity, its polysaccharide extract can enhance and regulate T cell and macrophage, such as increasing NO production and increasing cytokinses (IL-1 β and TNF-β). This effect may be the polysaccharide extract of Hericium erinaceus. One of the reasons for cancer resistance. In addition, several papers have been published to verify their role in neuroprotection, such as the monkey head. The mushroom ethanol extract can regulate and promote the mRNA expression of NGF through JNK pathway. This study is beneficial to the treatment of dementia and cognitive dysfunction diseases. The results show that short-term spatial and visual identification is induced by amyloid β(25-35)peptides. In ICR mice with impaired memory, the monkey mushroom powder can be used to prevent damage to the nerves. The results of clinical trials in Japan indicate that oral administration of Hericium erinaceus powder to subjects with mild cognitive impairment between the ages of 50 and 80 can improve the score on the cognitive function scale, and the results show that Hericium erinaceus delays functional degradation of the brain. The efficacy, and the value of further research and development.

However, the consumption of medicinal materials is mostly stewed or ground. The efficiency of the method is only 10~30%. At present, there is also a technology of ultra-fine preparation, although the effective utilization rate can be improved, but due to the increased cell wall breaking rate of the ultra-fine preparation, the surface area of the broken-wall preparation increases, the shape is irregular, the fluidity and the dispersibility are poor, and it is easy to absorb moisture and stabilize. Inherent characteristics such as poor performance, there is still an improved demand in application. The powder which is pressed by the ultra-fine preparation technology is very sensitive to the pH. If the powder directly enters the human body, it may be affected by the bactericidal action of gastric acid or bile, and it will be destroyed before being absorbed by the human body, and the effect of the powder is greatly reduced because the human body cannot absorb it. And it is not easy to store. Therefore, how to overcome the above problems is worthy of consideration in the field of ordinary knowledge.

The present invention provides an embedded granule coated with the powder of Hericium erinaceus. The powder of Hericium erinaceus is coated with a layer of a gelatinous substance to avoid the influence of gastric acid and bile, and is beneficial to the intestine through the stomach. The body absorbs.

The present invention provides an embedded granule coated with a powder of Hericium erinaceus, comprising a plurality of Hericium erinaceus powder and a layer of a gelatinous substance. The Hericium erinaceus powder has a diameter ranging from 10 microns to 12 microns. The gelatinous substance layer coats the Hericium erinaceus powder. The edible shell layer coats the layer of the gelatinous substance.

The above-mentioned coated particles of the coated Hericium erinaceus powder further comprise an edible shell layer covering the gelatinous substance layer.

The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the dopamine content of the neurotransmitter in the striatum of the mouse was 226.80±66.03 ng/g.

The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the lipid peroxide malondialdehyde content of the mouse liver was 772.86±225.23 μM.

The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the carbonyl content of the mouse liver was 385.05±235.15 nmol/mg.

The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, and the mouse 8-oxodG content was 0.73±0.18 ng/mL.

The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the superoxide dismutase content in the blood of the mice was 89.68±2.71 U/ml.

100‧‧‧Encapsulated particles coated with Hericium erinaceus powder

110‧‧‧Herbal mushroom powder

120‧‧‧Colloidal layer

130‧‧‧ edible shell

Figure 1 shows the analysis of the content of the neurotransmitter dopamine in the striatal tissue of the administration group.

Figure 2 shows the analysis of the content of MDA in the liver tissue of the administration group.

Figure 3 shows the analysis of the content of carbonyl groups in the liver tissue of the administration group.

Figure 4 shows the analysis of 8-oxodG content in liver tissue of the administration group.

Figure 5 shows the analysis of SOD enzyme activity in the blood of the administration group.

Figure 6 shows the analysis of Catalase enzyme activity in the blood of the administration group.

Figure 7 shows the analysis of G6PDH enzyme activity in the blood of the administration group.

Figure 8 shows the analysis of GPx enzyme activity in the blood of the administration group.

Figure 9 shows the analysis of GRd enzyme activity in the blood of the administration group.

Figure 10 depicts the embedded particles of the coated Hericium erinaceus powder of the present invention.

Please refer to FIG. 10 , which illustrates the embedded particles of the coated Hericium erinaceus powder of the present invention. The embedded particles coated with the Hericium erinaceus powder include a plurality of Hericium erinaceus powders 110, a gelatinous substance layer 120, and an edible casing layer 130. The gelatinous substance layer 120 is coated with the Hericium erinaceus powder 110, and the edible shell layer 130 is covered with the gelatinous substance layer 120. The gelatinous substance layer 120 and the edible shell layer 130 exhibit a multi-layered concentric structure, encapsulating the Hericium erinaceus powder 110, making it a sphere for convenient consumption by the user. And the Hericium erinaceus powder 110 is covered by the gelatinous substance layer 120 and the edible shell layer 130, thereby avoiding the influence of gastric acid and bile, and passing through the stomach to the intestinal tract, which is beneficial to the human body to absorb. Regarding the Hericium erinaceus powder 110, the description is as follows:

This creation evaluates the effect of different sizes of Hericium erinaceus powder on anti-aging effects by inducing aging mode-MPTP-induced animal model of Parkinson's disease. Interpretation of brain aging is based on the analysis of dopamine content in the most aging brain tissue striatum; blood samples are used for the determination of antioxidant biochemical indicators, including the determination of superoxide dismutase (SOD) activity, glucose Determination of glucose-6-phosphate dehydrogenase (G6PD) activity, determination of catalase activity, determination of glutathione peroxidase (GPx) activity and glutathione reduction Determination of the activity of glutathione reductase (GRd). In addition, liver tissue is also For the aging tissue, the 8-hydroxy-2-deoxyguanosine nucleus (8-oxodG) of mitochondrial DNA, the oxidatively modified protein carbonyl functional group content and the lipid oxidized malondialdehyde TBARS quantitative analysis were determined.

The experiment was carried out in 6-week old C57BL/6 Narl (n=75) male mice purchased from the National Animal Center of Taiwan. It is housed in the Experimental Animal Center of the National Yangming University, with an ambient temperature of 24 ± 1 ° C and a 12: 12 hour light and dark cycle.

The administration conditions were divided into 5 groups, healthy blank group: no drug was given, equal volume of distilled water was given, once a day, 30 days. (n=15), disease blank group: MPTP 20 mg/kg, intraperitoneal injection once a day, 5days+ distilled water, once a day, 30days. (n=15), JWH001 group: MPTP 20mg/kg, intraperitoneal injection once a day, 5days+JWH001 powder, 1g/kg, once a day, 30days. (n=15), Medium powder group: MPTP 20mg/kg, intraperitoneal injection once a day, 5days+ medium powder, 1g/kg, once a day, 30days. (n=15), and coarse powder group: MPTP 20mg/kg, intraperitoneal injection once a day , 5days + coarse powder, 1g / kg, oral once a day, 30days. (n = 15).

The above JWH001 group is one embodiment of the creation, the particle diameter D50 ranges from 10 micrometers to 12 micrometers; the medium powder group has a particle diameter D50 ranging from 16 micrometers to 20 micrometers; and the coarse powder group has a particle diameter D50 ranging from 85 micrometers to 100 micrometers. . In one embodiment, the creation of a commercially available product of the Hericium erinaceus powder having a particle size D50 of 100 micrometers (strain source: BCRC Number: 36470), via a gas flow superfine pulverizer (Spiral Jet Mill, OM2 Micronizer, Sturtevant) , Int., Hanover, MA USA), under the operating conditions of a feed rate of 30-40 g/min, a grinding pressure of 90-100 PSIG and a feed pressure of 50-60 PSIG, micronization was carried out to a particle size D50 of 10 μm.

For the above 5 groups, the experimental design is as follows: (1) healthy control group/administer an equal volume of physiological saline: intraperitoneal injection for five days in physiological saline, and equal volume of distilled water for 30 days in the same way. The mouse brain was dissected, the surgical instrument removed the brain and liver tissue, and the striatum was separated into the centrifuge tube. All the collected samples were stored in a refrigerator at -20 °C before analysis. 1 mL of blood was collected by cardiac blood sampling. (2) disease control group / MPTP 20mg / kg, ip + to give an equal volume of distilled water: give MPTP 20mg / kg intraperitoneal injection for five days and synchronous pipe irrigation to give an equal volume of distilled water for thirty days, the thirtieth One day, the mouse brain was dissected, the surgical instrument removed the brain and liver tissue, and the striatum was separated into the centrifuge tube. All the collected samples were stored in a refrigerator at -20 °C before analysis. 1 mL of blood was collected by cardiac blood sampling. (3) Experimental group/MPTP 20mg/kg, ip+ to be given 1g/kg of Hericium erinaceus powder, po, QD: Give MPTP 20mg/kg intraperitoneally and synchronously to give the Hericium erinaceus powder 1g/kg for 5 days. From the sixth day, the rabbit mushroom powder was maintained for 1g/kg until 30 days. On the 31st day, the mouse brain was dissected. The surgical instrument removed the brain and liver tissue and separated the striatum for centrifugation. Inside the tube, all samples collected were stored in a -20 ° C freezer prior to analysis. 1 mL of blood was collected by cardiac blood sampling. (4) Experimental group/MPTP 20mg/kg, ip+ administered medium powder 1g/kg, po, QD: Give MPTP 20mg/kg intraperitoneal injection and synchronous tube feeding method to give the monkey mushroom powder 1g/kg for five days, sixth From day on, I will continue to give 1g/kg of Hericium erinaceus powder until 30 days. On the 31st day, the mouse brain will be dissected. The surgical instrument will remove the brain and liver tissue and separate the striatum into the centrifuge tube. All collected samples were stored in a refrigerator at -20 ° C before analysis. 1 mL of blood was collected by cardiac blood sampling. (5) experimental group / MPTP 20mg / kg, ip + to give crude powder 1g / kg, po, QD: give MPTP 20mg / kg intraperitoneal injection and synchronous tube feeding method to give the monkey mushroom powder 1g / kg for five days, the sixth From day on, I will continue to give 1g/kg of Hericium erinaceus powder until 30 days. On the 31st day, the mouse brain will be dissected. The surgical instrument will remove the brain and liver tissue and separate the striatum into the centrifuge tube. All collected samples were stored in a refrigerator at -20 ° C before analysis. 1 mL of blood was collected by cardiac blood sampling.

The MPTP was prepared at a concentration of 4 mg/ml in physiological saline, and the final dose was 20 mg/kg according to the body weight.

(Measurement of biological activity index of brain tissue aging)

For the determination of dopamine content in the striatum of the brain, the striatum sampling of the brain was first performed: 24 hours after the completion of the drug on the 30th day, the mice were intraperitoneally injected with 100 mg/kg urethane anesthesia, and blood was collected by cardiac blood sampling. The sample was placed in a centrifuge tube and placed on ice and stored at -80 °C. Then, the brain was cut open and the brain was taken out. The body was packed in a flammable green plastic bag and sent to the Yangming University Animal Center for incineration. The striatum was separated from the brain, immersed in the preservation solution, and stored at -80 °C before analysis. Next, prepare an analysis sample Product: The tissue was stored in a stock solution (Stock solution: 0.1M HClO4, 0.1 mM EDTA, 0.1 mM Na2S2O5). After homogenization, the supernatant was centrifuged (13000 rpm, 10 min), and the neurotransmitter dopamine in the striatum was analyzed by electrochemical analysis. Variety. Next, dopamine (DA) was separately analyzed and the standard line was purchased from Sigma Aldrich. The analysis conditions were as follows. The column was Suhshell C18, 100×4.6 mm, 2.6 μm; mobile phase (1 L, pH 3.74): 0.74 mM sodium-1-Octanesulfaoate (SOS), 100 mM. Phosphate sodium salt, 0.027 mM EDTA 2M potassium chloride and 60 mL methanol; detector: Decade II, using a glassy carbon electrode for a digital electrochemical amperometric detector with an applied potential of 650 mV vs. Ag/AgCl Flow rate: 500 μL/min; range: 5 nA; injection volume: 15 μL.

(Measurement of biological activity index of liver tissue)

For the determination of protein carbonyl content after hepatic oxidation modification, liver tissue sample configuration: dissect 200-300 mg of tissue. Rinse the tissue with phosphate buffered saline to remove any red blood cells or clots that contain significant amounts of hemoglobin, especially hemoglobin, which will interfere with the assay. The tissue was homogenized in 1-2 ml of cold buffer (i.e., 50 mM MES or phosphate, pH 7.0). Centrifuge at 10,000 xg for 15 minutes at 4 °C. The supernatant was removed and stored on ice. If not measured on the same day, frozen at -80 ° C, the sample will be stable for at least one month. The supernatant absorbance at 280 nm and 260 nm was examined to determine if there was a nucleic acid present in the contaminated sample. Use a homogenization buffer for a blank. If the ratio 280/260 is less than 1, the step of further removing the nucleic acid requires 1% streptomycin sulfate.

For determination of liver lipid oxidized malondialdehyde TBARS content, liver tissue sample configuration: Weigh approximately 25 mg of tissue into a 1.5 ml centrifuge tube. 250 μl of protease-containing RIPA buffer selection inhibitor was added. Ultrasonic processing on ice for 15 seconds at 40V. The tube was centrifuged at 1,600 x g for 10 minutes at 4 °C. Use the supernatant for analysis. Store the supernatant on ice. If not measured on the same day, the sample will be stable for one month after freezing at -80 ° C. The tissue homogenate does not need to be diluted before the assay.

For liver 8-oxodG content determination, liver tissue sample configuration: Weigh approximately 25 mg of tissue into a 1.5 ml centrifuge tube. Add 1000 μl sucrose solution buffer, if not measured on the same day, freeze at -80 ° C, the sample will be stable for one month.

(Measurement of antioxidant biochemical indicators)

Regarding blood superoxide dismutase (SOD), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not frozen on the same day and at -80 ° C, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

Regarding blood glucose hexaphosphate dehydrogenase (G6PDH), blood sample configuration: blood is collected using an anticoagulant such as heparin or EDTA. It was centrifuged at 1,000 x g for 10 minutes at 4 °C. Remove the top plasma and buffy coat. Red blood cells were diluted 1:1 with phosphate buffered saline (pH 7.4) and placed in ice (i.e., 1 ml of red blood cells and 1 ml of buffer). On ice, red blood cells were sonicated with a small amount of short pulses to break the cells. If not measured on the same day, freeze at -80 °C. The sample will be stable for one month and stored at -80 °C. The lysate was further diluted 1:10:20 with assay buffer prior to assay.

For blood catalase activity assay (Catalase), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not on the same day and at -80 ° C cold After freezing, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

Regarding blood glutathione peroxidase (GPx), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not frozen on the same day and at -80 ° C, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

Regarding blood glutathione reductase (GRd), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not frozen on the same day and at -80 ° C, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

The results of the bioactivity indicators of brain tissue aging were as follows. After comparing the striatum of the mice in the five groups and the disease group, it was found that the oral administration of the extract of JMH001 powder 1g/kg, DA increased (P< 0.001), shown to effectively improve the dopamine content of neurotransmitters in the striatum. The striatum neurotransmitter content of the drug-administered group was analyzed (Fig. 1 and Table 1).

The results of the bioactivity index of liver tissue were as follows. After comparing the five groups of the drug group and the disease group, it was found that the JWH001 powder was orally administered at 1 g/kg, MP 1 g/kg, and the lipid peroxide malondialdehyde (MDA) was decreased (P <0.05). The results of this experiment show that JWH001 or MP can effectively improve liver oxidation when taken orally at 1g/kg. The experimental results showed that the MDA of JWH001 1g/kg and 1g/kg group was even lower than that of the healthy group, and the statistics were significantly different. (Figure 2 and Table 2). After comparing the five groups of the drug-administered group and the disease group, it was found that the JWH001 powder was orally administered at 1 g/kg, MP 1 g/kg and RP 1 g/kg, and the carbonyl content was decreased (P < 0.001). The results of this experiment show that JWH001 powder, MP, RP oral 1g / kg, can effectively improve liver lipid oxidation. The experimental results are shown in Figure 3 and Table 3. After comparing the five groups of the drug-administered group and the disease group, it was found that there was no significant difference between the oral administration of JWH001 powder 1g/kg, MP 1g/kg and RP 1g/kg, and 8-oxodG (P>0.05). The results of this experiment show that JWH001 powder, MP, RP oral 1g / kg, can effectively improve liver lipid oxidation. The experimental results are shown in Figure 4 and Table 4.

The results of antioxidative biochemical indicators were as follows. After comparing the five groups of the drug group and the disease group, it was found that the G6PDH, GRd, and GPx in the JWH001 1g/kg group increased (P<0.05), but the results of SOD and Catalase experiments were not statistical. Significant difference. (Figures 5 to 9 and Table 5).

Compared with the MPTP+H2O group, "*" P<0.05, "**" P<0.01, "***" P<0.001

Superfine pulverization technology is a new technology that has developed rapidly in recent years. For example, most of the active ingredients in Chinese herbal medicines are distributed in cells. When the conventional decoction pieces are boiled, only some of the active ingredients can be released. The utilization rate of the active ingredients is 10-30%, and the ultrafine grinding technology is used, such as crushing the Chinese medicine pieces to About 300 mesh, cells The breaking rate will reach 86.7%, which will improve the dissolution of the active ingredients in the medicinal materials, greatly enhance its efficacy, and the utilization rate of active ingredients will be above 90%, which will reduce the use of medicinal materials and protect the resources of medicinal materials, and at the same time increase the quality of medicines. Drug effect. This creation uses the ultrafine pulverization technique to crush the Hericium erinaceus powder 110 to a diameter of 10 micrometers to 12 micrometers. It has been experimentally proven that the larvae powder 110 having a diameter of 10 micrometers to 12 micrometers can effectively improve the utilization ratio of the components. At the same time, the gelatinous substance layer 120 and the edible shell layer 130 are used to coat the Hericium erinaceus powder 110 to avoid the influence of gastric acid and bile, and pass through the stomach to the intestinal tract, which is beneficial to the human body to absorb.

The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the scope of the patents of the present invention. Other equivalent variations of the patent spirit using the present invention are all within the scope of the patent.

Claims (6)

An embedded granule coated with a powder of Hericium erinaceus, comprising: a plurality of Hericium erinaceus powders having a diameter ranging from 10 micrometers to 12 micrometers; a gelatinous substance layer coating the powder of the Hericium erinaceus And an edible shell layer covering the gelatinous substance layer. The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the dopamine content of the neurotransmitter in the striatum of the mouse was 226.80±66.03 ng/g. . The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the lipid peroxide malondialdehyde content of the mouse liver was 772.86±225.23 μM. The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the carbonyl content of the mouse liver was 385.05±235.15 nmol/mg. The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, and the mouse 8-oxodG content was 0.73±0.18 ng/mL. The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the superoxide dismutase content in the blood of the mice was 89.68±2.71 U/ml.